Literature DB >> 16751138

Loss of factor VIII and von Willebrand factor activities during cold storage of whole blood is reversed by rewarming.

Majed A Refaai1, Elisabeth M Van Cott, Michael Lukoszyk, James Hughes, Charles S Eby.   

Abstract

Documentation of preanalytical conditions that could result in inaccurate results and misdiagnoses of patients is important. It has recently been reported that a significant loss of factor VIII (FVIII) and von Willebrand factor (vWF) activity occurs when citrated whole blood is stored on ice. We tested the hypothesis that the cold-dependent loss of FVIII and vWF activity is due to the formation of cryoprecipitate and is reversed by rewarming the citrated whole blood before centrifugation and removal of plasma. We collected venous blood from 10 healthy subjects into 3.2% sodium citrate glass tubes. One tube was immediately centrifuged and the plasma was stored at -20 degrees C. Following storage in an ice bath (4 degrees C) for 3.5 hours, 1 tube was immediately centrifuged and processed while the second tube was placed in a 37 degrees C water bath for 5 minutes then centrifuged and processed. Subsequently, plasma samples were quickly thawed at 37 degrees C and the following tests were performed: prothrombin time (PT), partial thrombin time (aPTT), FVIII activity, vWF antigen (vWF:Ag), and vWF activity (vWF:Act). Means for each analyte from the 2 tubes stored at 4 degrees C for 3.5 hours with or without rewarming were compared to baseline tube using the Student t test. Compared to the baseline tube results, PT and aPTT showed no significant changes in either of the tubes stored at 4 degrees C for 3.5 hours. However, FVIII, vWF:Ag, and vWF:Act were significantly lower in the tubes stored at 4 degrees C for 3.5 hours, but no differences were detected between baseline and rewarmed tube results. In conclusion, prolonged storage of citrated whole blood at 4 degrees C causes a clinically significant reduction of FVIII and vWF activities. The losses are completely reversed by rewarming the tube prior to processing. This is consistent with a reversible cryoprecipitation of vWF and FVIII rather than a cold-activated enzymatic degradation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751138     DOI: 10.1532/LH96.05043

Source DB:  PubMed          Journal:  Lab Hematol        ISSN: 1080-2924


  4 in total

Review 1.  Designing and managing a flexible and dynamic biorepository system: a 15-year perspective from the CPCRA, ESPRIT, and INSIGHT clinical trial networks.

Authors:  Katherine H Hullsiek; Michelle George; Shawn K Brown
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

2.  Thawing of Pooled, Solvent/Detergent-Treated Plasma octaplasLG®: Validation Studies Using Different Thawing Devices.

Authors:  Andrea Heger; Katharina Pock; Jürgen Römisch
Journal:  Transfus Med Hemother       Date:  2017-03-14       Impact factor: 3.747

3.  Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".

Authors:  Jason M Meunier; Evan Wenker; Christopher J Lindsell; George J Shaw
Journal:  Acad Emerg Med       Date:  2013-05       Impact factor: 3.451

4.  Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.

Authors:  Giuseppe Lippi; Massimo Franchini; Gian Luca Salvagno; Martina Montagnana; Giovanni Poli; Gian Cesare Guidi
Journal:  J Thromb Thrombolysis       Date:  2007-09-03       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.